The present invention features solid compositions comprising Compound IA, IB, IC or ID, or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound IA, IB, IC or ID, or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.